Cancer Research and Treatment

Original Articles

Breast cancer

A Real-world Efficacy of Nab-paclitaxel Monotherapy in Metastatic Breast Cancer: Jung Sun Kim, Koung Jin Suh, Dae-Won Lee, Go-un Woo, Miso Kim, Se Hyun Kim, Han Suk Ryu, Kyung-Hun Lee, Tae-Yong Kim, Sae-Won Han, So Yeon Park, In Ae Park, Jee Hyun Kim, Seock-Ah Im; Cancer Res Treat. 2022;54(2):488-496. Published online August 13, 2021; DOI: https://doi.org/10.4143/crt.2021.394

Purpose
We aimed to assess the real-world efficacy of nab-paclitaxel in metastatic breast cancer patients.
Materials and Methods
This is a retrospective study performed in two tertiary referral hospitals in Korea. Patients with metastatic breast cancer treated with nab-paclitaxel (Abraxane®) between March 2016 and March 2020 were enrolled.
Results
A total of 102 patients with metastatic breast cancer were included. Patients were heavily pre-treated with a median of four prior lines of chemotherapy (5 lines when including endocrine therapy in hormone-receptor-positive patients), and 66 patients (64.7%) were exposed to taxanes in the metastatic setting. According to St. Gallen molecular subtypes, 36 patients (35.3%) were luminal A, 28 (27.5%) were luminal B, 18 (17.7%) were human epidermal growth factor receptor 2–positive and 20 (19.6%) had triple-negative disease. Fifty patients (49.0%) were treated with a 3-weekly regimen (260 mg/m² on day 1 every 3 weeks), and 52 (51.0%) were treated with a weekly regimen (100 mg/m² every week). Objective response rate was 22.9%. After a median follow-up of 22.0 months, median progression-free survival (PFS) was 4.0 months (95% confidence interval [CI], 2.6 to 4.8) and median overall survival was 8.7 months (95% CI, 7.5 to 11.2). Patients treated with weekly regimen had longer PFS compared to 3-weekly regimen (5.5 vs. 2.3 months, p < 0.001). Multivariate analysis revealed the treatment regimen as an independent prognostic factor for PFS. There was no grade 3 or 4 hypersensitivity reaction.
Conclusion
This real-world data shows that nab-paclitaxel is a reasonable treatment option in heavily pre-treated and/or taxane-exposed metastatic breast cancer patients.

Citations

Citations to this article as recorded by

Long-term outcomes of a randomized, open-label, phase II study comparing cabazitaxel versus paclitaxel as neoadjuvant treatment in patients with triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE)
P. Meyer-Wilmes, J. Huober, M. Untch, J.-U. Blohmer, W. Janni, C. Denkert, P. Klare, T. Link, K. Rhiem, C. Bayer, M. Reinisch, V. Bjelic-Radisic, D.M. Zahm, C. Hanusch, C. Solbach, G. Heinrich, A.D. Hartkopf, A. Schneeweiss, P. Fasching, N. Filmann, V. Ne
ESMO Open.2024; 9(5): 103009. CrossRef
Real-world study on the effect of nab-paclitaxel treatment on clinical outcomes and laboratory parameters in patients across metastatic tumor sites
Vikas Talreja, Sangeeta Khetwani, Ethirajan Nanadagopal, Nilesh Eknath Borkar, Kunal Khobragade
International Journal of Molecular and Immuno Oncology.2024; 9: 46. CrossRef
Safety and efficacy of generic nab-paclitaxel-based therapy in Chinese patients with malignant tumors in a real-world setting: a multicenter prospective observational study
Fei He, Yancai Sun, Wenzhou Zhang, Qiongshi Wu, Donghang Xu, Zaixian Bai, Zhiying Hao, Weiyi Feng, Kanghuai Zhang, Jiang Liu, Mei Dong, Guangxuan Liu, Guohui Li
Discover Oncology.2024;[Epub] CrossRef
Nanoparticle albumin-bound paclitaxel and PD-1 inhibitor (sintilimab) combination therapy for soft tissue sarcoma: a retrospective study
Zhichao Tian, Shuping Dong, Yang Yang, Shilei Gao, Yonghao Yang, Jinpo Yang, Peng Zhang, Xin Wang, Weitao Yao
BMC Cancer.2022;[Epub] CrossRef
Paclitaxel

Reactions Weekly.2022; 1926(1): 383. CrossRef
Natural Taxanes: From Plant Composition to Human Pharmacology and Toxicity
Ľuboš Nižnanský, Denisa Osinová, Roman Kuruc, Alexandra Hengerics Szabó, Andrea Szórádová, Marián Masár, Žofia Nižnanská
International Journal of Molecular Sciences.2022; 23(24): 15619. CrossRef
A Novel Microcrystalline BAY-876 Formulation Achieves Long-Acting Antitumor Activity Against Aerobic Glycolysis and Proliferation of Hepatocellular Carcinoma
Hua Yang, Mu-Zi-he Zhang, Hui-wei Sun, Yan-tao Chai, Xiaojuan Li, Qiyu Jiang, Jun Hou
Frontiers in Oncology.2021;[Epub] CrossRef

7,152 View
220 Download
5 Web of Science
7 Crossref

Can We Skip Intraoperative Evaluation of Sentinel Lymph Nodes? Nomogram Predicting Involvement of Three or More Axillary Lymph Nodes before Breast Cancer Surgery: Soo Kyung Ahn, Min Kyoon Kim, Jongjin Kim, Eunshin Lee, Tae-Kyung Yoo, Han-Byoel Lee, Young Joon Kang, Jisun Kim, Hyeong-Gon Moon, Jung Min Chang, Nariya Cho, Woo Kyung Moon, In Ae Park, Dong-Young Noh, Wonshik Han; Cancer Res Treat. 2017;49(4):1088-1096. Published online January 25, 2017; DOI: https://doi.org/10.4143/crt.2016.473

Abstract PDF Supplementary Material PubReader ePub

Purpose
The American College of Surgeons Oncology Group Z0011 trial reported that complete dissection of axillary lymph nodes (ALNs) may not be warranted in women with clinical T1-T2 tumors and one or two involved ALNs who were undergoing lumpectomy plus radiation followed by systemic therapy. The present study was conducted to identify preoperative imaging predictors of ≥ 3 ALNs.
Materials and Methods
The training set consisted of 1,917 patients with clinical T1-T2 and node negative invasive breast cancer. Factors associated with ≥ 3 involved ALNs were evaluated by logistic regression analysis. The validation set consisted of 378 independent patients. The nomogram was applied prospectively to 512 patients who met the Z0011 criteria.
Results
Of the 1,917 patients, 204 (10.6%) had ≥ 3 positive nodes. Multivariate analysis showed that involvement of ≥ 3 nodes was significantly associated with ultrasonographic and chest computed tomography findings of suspicious ALNs (p < 0.001 each). These two imaging criteria, plus patient age, were used to develop a nomogram calculating the probability of involvement of ≥ 3 ALNs. The areas under the receiver operating characteristic curve of the nomogram were 0.852 (95% confidence interval [CI], 0.820 to 0.883) for the training set and 0.896 (95% CI, 0.836 to 0.957) for the validation set. Prospective application of the nomogram showed that 60 of 512 patients (11.7%) had scores above the cut-off. Application of the nomogram reduced operation time and cost, with a very low re-operation rate (1.6%).
Conclusion
Patients likely to have ≥ 3 positive ALNs could be identified by preoperative imaging. The nomogram was helpful in selective intraoperative examination of sentinel lymph nodes.

Citations

Citations to this article as recorded by

Predicting three or more metastatic nodes using contrast-enhanced lymphatic US findings in early breast cancer
Zihan Niu, Yunxia Hao, Yuanjing Gao, Jing Zhang, Mengsu Xiao, Feng Mao, Yidong Zhou, Ligang Cui, Yuxin Jiang, Qingli Zhu
Insights into Imaging.2024;[Epub] CrossRef
Individualized prediction of non-sentinel lymph node metastasis in Chinese breast cancer patients with ≥ 3 positive sentinel lymph nodes based on machine-learning algorithms
Xiangli Xie, Yutong Fang, Lifang He, Zexiao Chen, Chunfa Chen, Huancheng Zeng, Bingfeng Chen, Guangsheng Huang, Cuiping Guo, Qunchen Zhang, Jundong Wu
BMC Cancer.2024;[Epub] CrossRef
Gail model and fifth edition of ultrasound BI‐RADS help predict axillary lymph node metastasis in breast cancer—A multicenter prospective study
Lu‐Ying Gao, Hai‐Tao Ran, You‐Bin Deng, Bao‐Ming Luo, Ping Zhou, Wu Chen, Yu‐Hong Zhang, Jian‐Chu Li, Hong‐Yan Wang, Yu‐Xin Jiang
Asia-Pacific Journal of Clinical Oncology.2023;[Epub] CrossRef
Nomogram based on multiparametric analysis of early‐stage breast cancer: Prediction of high burden metastatic axillary lymph nodes
Ling Li, Jing Zhao, Yu Zhang, Zhanyu Pan, Jin Zhang
Thoracic Cancer.2023; 14(35): 3465. CrossRef
Stratification of Axillary Lymph Node Metastasis Risk with Breast MRI in Breast Cancer
Jieying Chen, Xiaolian Su, Tingting Xu, Qifeng Luo, Lin Zhang, Guangyu Tang
Future Oncology.2022; 18(15): 1849. CrossRef
ACR Appropriateness Criteria® Imaging of the Axilla
Huong T. Le-Petross, Priscilla J. Slanetz, Alana A. Lewin, Jean Bao, Elizabeth H. Dibble, Mehra Golshan, Jessica H. Hayward, Charlotte D. Kubicky, A. Marilyn Leitch, Mary S. Newell, Christine Prifti, Matthew F. Sanford, John R. Scheel, Richard E. Sharpe,
Journal of the American College of Radiology.2022; 19(5): S87. CrossRef
Avoiding unnecessary intraoperative sentinel lymph node frozen section biopsy of patients with early breast cancer
Jongwon Kang, Tae-Kyung Yoo, Ahwon Lee, Jun Kang, Chang Ik Yoon, Bong Joo Kang, Sung Hun Kim, Woo Chan Park
Annals of Surgical Treatment and Research.2022; 102(5): 241. CrossRef
A nomogram for predicting three or more axillary lymph node involvement before breast cancer surgery
Young-Joon Kang, Jung Hyun Park, Young Wook Ju, Kyoung-Eun Kim, Yumi Kim, Eunshin Lee, Han-Byoel Lee, Dong-Young Noh, Wonshik Han
Scientific Reports.2022;[Epub] CrossRef
Accurate Evaluation of Feature Contributions for Sentinel Lymph Node Status Classification in Breast Cancer
Angela Lombardi, Nicola Amoroso, Loredana Bellantuono, Samantha Bove, Maria Colomba Comes, Annarita Fanizzi, Daniele La Forgia, Vito Lorusso, Alfonso Monaco, Sabina Tangaro, Francesco Alfredo Zito, Roberto Bellotti, Raffaella Massafra
Applied Sciences.2022; 12(14): 7227. CrossRef
Is Routine Intraoperative Frozen Section Analysis of Sentinel Lymph Nodes Necessary in Every Early-Stage Breast Cancer?
Bhoowit Lerttiendamrong, Nattanan Treeratanapun, Voranaddha Vacharathit, Kasaya Tantiphlachiva, Phuphat Vongwattanakit, Sopark Manasnayakorn, Mawin Vongsaisuwon
Breast Cancer: Targets and Therapy.2022; Volume 14: 281. CrossRef
Predictive nomogram based on serum tumor markers and clinicopathological features for stratifying lymph node metastasis in breast cancer
Sheng-Kai Geng, Shao-Mei Fu, Hong-Wei Zhang, Yi-Peng Fu
BMC Cancer.2022;[Epub] CrossRef
Prediction of axillary nodal burden in patients with invasive lobular carcinoma using MRI
Su Min Ha, Jung Min Chang, Soo-Yeon Kim, Su Hyun Lee, Eun Sil Kim, Yeon Soo Kim, Nariya Cho, Woo Kyung Moon
Breast Cancer Research and Treatment.2021; 186(2): 463. CrossRef
Predicting of Sentinel Lymph Node Status in Breast Cancer Patients with Clinically Negative Nodes: A Validation Study
Annarita Fanizzi, Domenico Pomarico, Angelo Paradiso, Samantha Bove, Sergio Diotaiuti, Vittorio Didonna, Francesco Giotta, Daniele La Forgia, Agnese Latorre, Maria Irene Pastena, Pasquale Tamborra, Alfredo Zito, Vito Lorusso, Raffaella Massafra
Cancers.2021; 13(2): 352. CrossRef
Sentinel Lymph Node Metastasis on Clinically Negative Patients: Preliminary Results of a Machine Learning Model Based on Histopathological Features
Annarita Fanizzi, Vito Lorusso, Albino Biafora, Samantha Bove, Maria Colomba Comes, Cristian Cristofaro, Maria Digennaro, Vittorio Didonna, Daniele La Forgia, Annalisa Nardone, Domenico Pomarico, Pasquale Tamborra, Alfredo Zito, Angelo Virgilio Paradiso,
Applied Sciences.2021; 11(21): 10372. CrossRef
The new perspective of PET/CT for axillary nodal staging in early breast cancer patients according to ACOSOG Z0011 trial PET/CT axillary staging according to Z0011
Eunjung Kong, Jungeun Choi
Nuclear Medicine Communications.2021; 42(12): 1369. CrossRef
Clinical Value of Axillary Ultrasonography in Breast Cancer with Lymph Node Metastases
Jung Ho Park, Hyun Ryung Kim, Sanghwa Kim, Young Ah Lim, Kyoonsoon Jung, Lee Su Kim
Journal of Surgical Ultrasound.2021; 8(2): 41. CrossRef
Can a machine-learning model improve the prediction of nodal stage after a positive sentinel lymph node biopsy in breast cancer?
V. Madekivi, P. Boström, A. Karlsson, R. Aaltonen, E. Salminen
Acta Oncologica.2020; 59(6): 689. CrossRef
External validation of a prognostic model based on total tumor load of sentinel lymph node for early breast cancer patients
Antonio Piñero-Madrona, Francisco Ripoll-Orts, José Ignacio Sánchez-Méndez, Asunción Chaves-Benito, Maximiliano Rodrigo Gómez-de la Bárcena, Ana Calatrava-Fons, Salomón Menjón-Beltrán, Vicente Peg-Cámara
Breast Cancer Research and Treatment.2020; 181(2): 339. CrossRef
Axillary Nodal Evaluation in Breast Cancer: State of the Art
Jung Min Chang, Jessica W. T. Leung, Linda Moy, Su Min Ha, Woo Kyung Moon
Radiology.2020; 295(3): 500. CrossRef
Can We Identify or Exclude Extensive Axillary Nodal Involvement in Breast Cancer Patients Preoperatively?
Martijn Leenders, Gaëlle Kramer, Kamar Belghazi, Katya Duvivier, Petrousjka van den Tol, Hermien Schreurs
Journal of Oncology.2019; 2019: 1. CrossRef
Computer-aided prediction model for axillary lymph node metastasis in breast cancer using tumor morphological and textural features on ultrasound
Woo Kyung Moon, I-Ling Chen, Ann Yi, Min Sun Bae, Sung Ui Shin, Ruey-Feng Chang
Computer Methods and Programs in Biomedicine.2018; 162: 129. CrossRef
The Evolution of the Current Indications for Sentinel Lymph Node Biopsy in Breast Cancer
Sofia E Triantafillidou
Hellenic Journal of Surgery.2018; 90(4): 186. CrossRef
Axillary Lymph Node to Primary Breast Tumor Standardized Uptake Value Ratio from FDG-PET/CT Imaging for Predicting the Necessity for Nodal Dissection in Primary Breast Tumors
Han-kyul Shin, Min Kyoon Kim, Sung Jun Park, Ju Won Seok, Hee-Chul Shin
Journal of Breast Disease.2017; 5(2): 76. CrossRef

10,577 View
355 Download
21 Web of Science
23 Crossref

Nomogram for Predicting Breast Conservation after Neoadjuvant Chemotherapy: Min Kyoon Kim, Wonshik Han, Hyeong-Gon Moon, Soo Kyung Ahn, Jisun Kim, Jun Woo Lee, Ju-Yeon Kim, Taeryung Kim, Kyung-Hun Lee, Tae-Yong Kim, Sae-Won Han, Seock-Ah Im, Tae-You Kim, In Ae Park, Dong-Young Noh; Cancer Res Treat. 2015;47(2):197-207. Published online September 4, 2014; DOI: https://doi.org/10.4143/crt.2013.247

Abstract PDF PubReader ePub

Purpose
The ability to accurately predict the likelihood of achieving breast conservation surgery (BCS) after neoadjuvant chemotherapy (NCT) is important in deciding whether NCT or surgery should be the first-line treatment in patients with operable breast cancers. Materials and Methods We reviewed the data of 513 women, who had stage II or III breast cancer and received NCT and surgery from a single institution. The ability of various clinicopathologic factors to predict the achievement of BCS and tumor size reduction to ≤ 3 cm was assessed. Nomograms were built and validated in an independent cohort. Results BCS was performed in 50.1% of patients, with 42.2% of tumors reduced to ≤ 3 cm after NCT. A multivariate logistic regression analysis showed that smaller initial tumor size, longer distance between the lesion and the nipple, absence of suspicious calcifications on mammography, and a single tumor were associated with BCS rather than mastectomy (p < 0.05). Negative estrogen receptor, smaller initial tumor size, higher Ki-67 level, and absence of in situ component were associated with residual tumor size ≤ 3 cm (p < 0.05). Two nomograms were developed using these factors. The areas under the receiver operating characteristic curves for nomograms predicting BCS and residual tumor ≤ 3 cm were 0.800 and 0.777, respectively. The calibration plots showed good agreement between the predicted and actual probabilities. Conclusion We have established a model with novel factors that predicts BCS and residual tumor size after NCT. This model can help in making treatment decisions for patients who are candidates for NCT.

Citations

Citations to this article as recorded by

Risk scoring system for predicting breast conservation after neoadjuvant chemotherapy
Lobna Ouldamer, Sofiane Bendifallah, Joseph Pilloy, Flavie Arbion, Gilles Body, Caroline Brisson, Vincent Lavoué, Jean Lévêque, Emile Daraï
The Breast Journal.2019; 25(4): 696. CrossRef
Score for the Survival Probability in Metastasis Breast Cancer: A Nomogram-Based Risk Assessment Model
Zhenchong Xiong, Guangzheng Deng, Xinjian Huang, Xing Li, Xinhua Xie, Jin Wang, Zeyu Shuang, Xi Wang
Cancer Research and Treatment.2018; 50(4): 1260. CrossRef
Development of Nomogram to Predict the Best Military Category Using Physical Fitness Variables: A Model Development in Navy Trainees
Milad Nazarzadeh, Ali Reza Khoshdel, Abolfazl Goodarzi, Alireza Mosavi Jarrahi
Journal of Archives in Military Medicine.2018;[Epub] CrossRef
Predicting Successful Conservative Surgery after Neoadjuvant Chemotherapy in Hormone Receptor-Positive, HER2-Negative Breast Cancer
Chang Seok Ko, Kyu Min Kim, Jong Won Lee, Han Shin Lee, Sae Byul Lee, Guiyun Sohn, Jisun Kim, Hee Jeong Kim, Il Yong Chung, Beom Seok Ko, Byung Ho Son, Seung Do Ahn, Sung-Bae Kim, Hak Hee Kim, Sei Hyun Ahn
Journal of Breast Disease.2018; 6(2): 52. CrossRef
External validation of a published nomogram for prediction of brain metastasis in patients with extra-cerebral metastatic breast cancer and risk regression analysis
Ludivine Genre, Henri Roché, Léonel Varela, Dorra Kanoun, Monia Ouali, Thomas Filleron, Florence Dalenc
European Journal of Cancer.2017; 72: 200. CrossRef
Facteurs prédictifs de traitement conservateur après chimiothérapie néo-adjuvante dans le cancer du sein
J. Pilloy, C. Fleurier, M. Chas, L. Bédouet, M.L. Jourdan, F. Arbion, G. Body, L. Ouldamer
Gynécologie Obstétrique Fertilité & Sénologie .2017; 45(9): 466. CrossRef
Actual Conversion Rate from Total Mastectomy to Breast Conservation after Neoadjuvant Chemotherapy for Stages II–III Breast Cancer Patients
Hyejin Mo, Yumi Kim, Jiyoung Rhu, Kyung-Hun Lee, Tae-Yong Kim, Seock-Ah Im, Eun-Shin Lee, Han-Byoel Lee, Hyeong-Gon Moon, Dong-Young Noh, Wonshik Han
Journal of Breast Disease.2017; 5(2): 51. CrossRef

14,262 View
100 Download
4 Web of Science
7 Crossref

Case Report

Adenoid Cystic Carcinoma of the Breast: A Case Series of Six Patients and Literature Review: Miso Kim, Dae-Won Lee, Jin Im, Koung Jin Suh, Bhumsuk Keam, Hyeong-Gon Moon, Seock-Ah Im, Wonshik Han, In Ae Park, Dong-Young Noh; Cancer Res Treat. 2014;46(1):93-97. Published online January 15, 2014; DOI: https://doi.org/10.4143/crt.2014.46.1.93

Abstract PDF PubReader ePub

Adenoid cystic carcinoma (ACC) of the breast is a very rare and indolent tumor with a favorable prognosis, despite its triple-negative status. Due to its rarity, there has been no consensus regarding treatments, and treatment guidelines have not been established. Here, we report on six patients with ACC of the breast. All of the patients initially presented with localized disease and no axillary lymph node metastases. Although some of our patients developed local recurrence or distant metastases, all patients had a favorable clinical course, and to date, none of the patients has died from complications of her disease. Here, we described the clinicopathologic features of ACC of the breast and review the current literature.

Citations

Citations to this article as recorded by

MYB expression by immunohistochemistry is highly specific and sensitive for detection of solid variant of adenoid cystic carcinoma of the breast among all triple‐negative breast cancers
Harsh Batra, Priya S C Bose, Yang Ding, Alan Dai, Hui Chen, Constance T Albarracin, Hongxia Sun, Aysegul A Sahin, Fei Yang, Ignacio I Wistuba, Maria G Raso
Histopathology.2024; 85(3): 503. CrossRef
Adenoid Cystic Carcinoma of the Breast: Multimodality Imaging Findings and Review of the Literature
Nilgun Guldogan, Gul Esen, Yasemin Kayadibi, Fusun Taskin, Aysenur Oktay Alfatli, Fatma Nur Soylu Boy, Pinar Balci, Onur Bugdayci, Fatma Tokat, Tulin Ozturk, Mehtap Tunaci, Akif Enes Arikan
Academic Radiology.2023; 30(6): 1107. CrossRef
Optimal surgical procedure for treating early-stage adenoid cystic carcinoma of the breast
Tao Huang, Qigen Fang, Lianjie Niu, Lina Wang, Xianfu Sun
Scientific Reports.2023;[Epub] CrossRef
Locally Advanced Adenoid Cystic Carcinoma of the Breast—A Case Report with a Review of the Literature
Joanna Rypel, Paulina Kubacka, Joanna Mykała-Cieśla, Jacek Pająk, Weronika Bulska-Będkowska, Jerzy Chudek
Medicina.2023; 59(11): 2005. CrossRef
Adenoid Cystic Carcinoma of the Breast and Intraoperative Electron Radiotherapy: Single Case Report and Review of Literature
Giuseppe Accardo, Alba ML Capobianco, Giuseppe La Torre, Alexios Thodas, Graziella Marino, Leuconoe Grazia Sisti, Giulia Vita
Future Oncology.2022; 18(7): 871. CrossRef
Breast adenoid cystic carcinoma: a report of seven cases and literature review
Meilin Zhang, Yanbiao Liu, Hongguang Yang, Feng Jin, Ang Zheng
BMC Surgery.2022;[Epub] CrossRef
Adenoid cystic carcinoma and basaloid carcinoma of the breast: A clinicopathological study
Vicente Marco, Felip Garcia, Isabel T. Rubio, Teresa Soler, Laura Ferrazza, Ignasi Roig, Inmaculada Mendez, Xavier Andreu, Clarisa González Mínguez, Francesc Tresserra
Revista Española de Patología.2021; 54(4): 242. CrossRef
Management of Adenoid Cystic Carcinoma of the Breast: A Single-Institution Study
Wenxiang Zhang, Yi Fang, Zhihui Zhang, Jing Wang
Frontiers in Oncology.2021;[Epub] CrossRef
Adenoid Cystic Carcinoma of the Breast
Yun-Chung Cheung, Shir-Hwa Ueng, Shu-Hang Ng, Wen-Lin Kuo
Current Medical Imaging Formerly Current Medical Imaging Reviews.2021; 17(4): 539. CrossRef
Triple-Negative Breast Cancer Histological Subtypes with a Favourable Prognosis
Gábor Cserni, Cecily M. Quinn, Maria Pia Foschini, Simonetta Bianchi, Grace Callagy, Ewa Chmielik, Thomas Decker, Falko Fend, Anikó Kovács, Paul J. van Diest, Ian O. Ellis, Emad Rakha, Tibor Tot
Cancers.2021; 13(22): 5694. CrossRef
Adenoid Cystic Carcinoma Breast: a Rare Entity
Santosh Tummidi, Shubhra Prasad, Deepti Joshi, Ashwani Tandon, Anjaly Mohan, Pradeep Saxena, Neelkamal Kapoor
Indian Journal of Surgical Oncology.2020; 11(S2): 226. CrossRef
Adenoid cystic carcinoma of the breast
Devon N Thomas, Armand Asarian, Philip Xiao
Journal of Surgical Case Reports.2019;[Epub] CrossRef
Adenoid cystic carcinoma of the breast in a male
Wenyang Pang, Zhengyi Wang, Xiaoyan Jin, Qiang Zhang
Medicine.2019; 98(32): e16760. CrossRef
An unusual presentation of adenoid cystic carcinoma of the breast with metastatic disease in the clavicle
Thomas Edward Glover, Ryan Butel, Cara Manmeet Bhuller, Emma Louise Senior
BJR|case reports.2017; 3(2): 20160119. CrossRef
Adenoid cystic carcinoma of the breast – an aggressive presentation with pulmonary, kidney, and brain metastases: a case report
Hasnae Alaoui Mhamdi, Hampig Raphael Kourie, Christiane Jungels, Philippe Aftimos, Rhizlane Belbaraka, Martine Piccart-Gebhart
Journal of Medical Case Reports.2017;[Epub] CrossRef
Adenoid cystic carcinoma: A review of recent advances, molecular targets, and clinical trials
Patrick M. Dillon, Samhita Chakraborty, Christopher A. Moskaluk, Prashant J. Joshi, Christopher Y. Thomas
Head & Neck.2016; 38(4): 620. CrossRef
Pleomorphic adenoma‐like tumour of the breast
Emad A Rakha, Mohammed A Aleskandarany, Rehab M Samaka, Zsolt Hodi, Andrew H S Lee, Ian O Ellis
Histopathology.2016; 68(3): 405. CrossRef
Breast lesions of uncertain malignant nature and limited metastatic potential: proposals to improve their recognition and clinical management
Emad A Rakha, Sunil Badve, Vincenzo Eusebi, Jorge S Reis‐Filho, Stephen B Fox, David J Dabbs, Thomas Decker, Zsolt Hodi, Shu Ichihara, Andrew HS Lee, José Palacios, Andrea L Richardson, Anne Vincent‐Salomon, Fernando C Schmitt, Puay‐Hoon Tan, Gary M Tse,
Histopathology.2016; 68(1): 45. CrossRef
A rare case of adenoid cystic carcinoma of the breast detected by 18F-FDG PET/CT
G. Treglia, F. Bertagna, L. Ceriani, L. Giovanella
Revista Española de Medicina Nuclear e Imagen Molecular.2015; 34(3): 205. CrossRef
A rare case of adenoid cystic carcinoma of the breast detected by 18F-FDG PET/CT
G. Treglia, F. Bertagna, L. Ceriani, L. Giovanella
Revista Española de Medicina Nuclear e Imagen Molecular (English Edition).2015; 34(3): 205. CrossRef
Radiologic and Pathological Correlation of Adenoid Cystic Carcinoma of the Breast: A Case Report
Jung Gyu Kim, Shin Young Kim, Hae Yoen Jung, Sung Yong Kim, Deuk Young Lee, Sang Hyun Park
Journal of the Korean Society of Radiology.2015; 72(6): 411. CrossRef
Imaging Manifestation of Adenoid Cystic Carcinoma of the Breast
Wei Tang, Wei Jun Peng, Ya Jia Gu, Hui Zhu, Ting Ting Jiang, Can Li
Journal of Computer Assisted Tomography.2015; 39(4): 523. CrossRef
Adenoid cystic carcinoma of the breast from a single-center cohort
Elizabeth Kander, Sania Raza, Sagar Dhamne, Mariana Solari, Sarika Jain
Cancer Treatment Communications.2015; 4: 182. CrossRef
Breast Neoplasms with Dermal Analogue Differentiation (Mammary Cylindroma): Report of 3 Cases and a Proposal for a New Terminology
Emad A. Rakha, Andrew H.S. Lee, Rachael Sheeran, Chris Abbosh, Zsolt Hodi, Will Merchant, Ian O. Ellis, Abeer M. Shaaban
Pathobiology.2015; 82(3-4): 172. CrossRef
Influence of Ribosomal Protein L39-L in the Drug Resistance Mechanisms of Lacrimal Gland Adenoid Cystic Carcinoma Cells
Qing Ye, Shao-Feng Ding, Zhi-An Wang, Jie Feng, Wen-Bin Tan
Asian Pacific Journal of Cancer Prevention.2014; 15(12): 4995. CrossRef
Adenoid cystic carcinoma of breast: Recent advances
Kosuke Miyai
World Journal of Clinical Cases.2014; 2(12): 732. CrossRef

15,858 View
102 Download
26 Web of Science
26 Crossref

Original Articles

The Relationship between Expression of the Sodium/iodide Symporter Gene and the Status of Hormonal Receptors in Human Breast Cancer Tissue: Hyun Jung Oh, June-Key Chung, Joo Hyun Kang, Won Jun Kang, Dong Young Noh, In Ae Park, Jae Min Jeong, Dong Soo Lee, Myung Chul Lee; Cancer Res Treat. 2005;37(4):247-250. Published online August 31, 2005; DOI: https://doi.org/10.4143/crt.2005.37.4.247

Abstract PDF PubReader ePub

Purpose

It has been reported that the sodium/iodide symporter (NIS) gene is expressed in several breast cancer tissues, suggesting the possibility of radionuclide imaging and therapy. However, the regulatory mechanism of NIS gene expression in breast cancer is not yet understood. To assess the relationship between the hormonal status and the NIS expression in breast cancer tissue, we investigated the NIS expression and correlated it to the expression of the thyrotropin receptor (thyroid stimulating hormone receptor, TSH-R), the estrogen receptor (ER) and the progesterone receptor (PR) in human breast cancer tissues.

Materials and Methods

Breast cancer tissues were obtained from 44 patients. Pathological examination showed 2 cases of Grade I, 17 of Grade II, 22 of Grade III, and 3 of unknown grade. We measured the expression of NIS and TSH-R genes by using RT-PCR and we measured the status of ER and PR by using immunohistochemistry.

Results

The NIS gene was expressed in 15 (34%) of the 44 breast cancer tissues. The NIS gene was expressed in 32% of the cases with TSH-R gene expression. The NIS gene was expressed in 40% of the breast cancer tissues with a positive PR and in 31% with a negative PR (p>0.05). It was positive for PR in 18% of the cases and negative for PR in 39% of the cases (p>0.05).

Conclusion

The NIS gene is expressed in approximately one-third of the human breast cancer tissues. Its expression was not related to the presence of the TSH-R gene or hormonal receptors, ER and PR.

Citations

Citations to this article as recorded by

Benign thyroid disease and the risk of breast cancer: An updated systematic review and meta-analysis
Mingyue Han, Yao Wang, Yuanhui Jin, Xue Zhao, Haiying Cui, Guixia Wang, Xiaokun Gang
Frontiers in Endocrinology.2022;[Epub] CrossRef
Links between Breast and Thyroid Cancer: Hormones, Genetic Susceptibility and Medical Interventions
Man Lu, Hanqing Liu, Bilian Zheng, Shengrong Sun, Chuang Chen
Cancers.2022; 14(20): 5117. CrossRef
Competitive Endogenous Role of the LINC00511/miR-185-3p Axis and miR-301a-3p From Liquid Biopsy as Molecular Markers for Breast Cancer Diagnosis
Marwa M. Mahmoud, Eman F. Sanad, Reham A.A. Elshimy, Nadia M. Hamdy
Frontiers in Oncology.2021;[Epub] CrossRef
The correlation between breast cancer and urinary iodine excretion levels
Fatma Umit Malya, Huseyin Kadioglu, Mustafa Hasbahceci, Kemal Dolay, Mehmet Guzel, Yeliz Emine Ersoy
Journal of International Medical Research.2018; 46(2): 687. CrossRef
Different expression of sodium–iodide importer (NIS) between lactating breast and thyroid tissues may be due to structural difference of thyroid-stimulating hormone receptor (TSHR)
X.-Z. Shi, L. Xue, X. Jin, P. Xu, S. Jia, H.-M. Shen
Journal of Endocrinological Investigation.2017; 40(1): 41. CrossRef
Is there an association between thyroid function abnormalities and breast cancer?
Anna Angelousi, Evanthia Diamanti-Kandarakis, Evangelia Zapanti, Afroditi Nonni, Eftuxios Ktenas, Aimilia Mantzou, Konstantinos Kontzoglou, Grigorios Kouraklis
Archives of Endocrinology and Metabolism.2017; 61(1): 54. CrossRef
Iodide transport and breast cancer
Vikki L Poole, Christopher J McCabe
Journal of Endocrinology.2015; 227(1): R1. CrossRef
The prognosis and treatment of primary thyroid cancer occurred in breast cancer patients: comparison with ordinary thyroid cancer
Chang Min Park, Young Don Lee, Eun Mee Oh, Kwan-Il Kim, Heung Kyu Park, Kwang-Pil Ko, Yoo Seung Chung
Annals of Surgical Treatment and Research.2014; 86(4): 169. CrossRef
Sodium iodide symporter (NIS) in extrathyroidal malignancies: focus on breast and urological cancer
Salvatore Micali, Stefania Bulotta, Cinzia Puppin, Angelo Territo, Michele Navarra, Giampaolo Bianchi, Giuseppe Damante, Sebastiano Filetti, Diego Russo
BMC Cancer.2014;[Epub] CrossRef
TSH receptor antibodies have predictive value for breast cancer – retrospective analysis
Paweł Szychta, Wojciech Szychta, Adam Gesing, Andrzej Lewiński, Małgorzata Karbownik-Lewińska
Thyroid Research.2013;[Epub] CrossRef
Quantitative Immunohistochemical Analysis Reveals Association between Sodium Iodide Symporter and Estrogen Receptor Expression in Breast Cancer
Sushmita Chatterjee, Renu Malhotra, Frency Varghese, Amirali B. Bukhari, Asawari Patil, Ashwini Budrukkar, Vani Parmar, Sudeep Gupta, Abhijit De, Pranela Rameshwar
PLoS ONE.2013; 8(1): e54055. CrossRef
Microarray analysis of genes associated with cell surface NIS protein levels in breast cancer
Sasha J Beyer, Xiaoli Zhang, Rafael E Jimenez, Mei-Ling T Lee, Andrea L Richardson, Kun Huang, Sissy M Jhiang
BMC Research Notes.2011;[Epub] CrossRef
Do cell surface trafficking impairments account for variable cell surface sodium iodide symporter levels in breast cancer?
S. J. Beyer, R. E. Jimenez, C. L. Shapiro, J. Y. Cho, S. M. Jhiang
Breast Cancer Research and Treatment.2009; 115(1): 205. CrossRef

11,341 View
64 Download
13 Crossref

p53 and bcl-2 Gene Expression in Gastational Trophoblastic Disease: Noh Hyun Park, Ju Won Roh, Jae Weom Kim, Yong Sang Song, In Ae Park, Soon Beom Kang, Hyo Pyo Lee; J Korean Cancer Assoc. 1999;31(3):582-589.

Abstract PDF: PURPOSE
p53 and bcl-2 expressions are known as important cell survival factors and their levels of expression are related with patients prognosis in various human malignancies. But there are few data about p53 and bcl-2 expression and their role in the genesis of gestational trophoblastic disease (GTD). The aims of this study are to describe p53 and bcl-2 expression in normal trophoblast and hydatidifonn mole (HM), and to identify the role of p53 and bcl-2 in the genesis of gestational trophoblastic tumor (GlTI from HM.
MATERIALS AND METHODS
Paraffin-embedded tissue sections from 32 cases of HM and 9 cases of normal early pregnancy placentas were obtained. Of 32 HM patients, 15 cases were cured after molar evacuation (group A), and 17 cases progressed to GT1' (group B). p53 and bcl-2 immunohistochemical stainings were done and their reactivity were graded. The positive rates of p53 and bcl-2 overexpression among normal placenta, group A, and group B were compared and analyzed.
RESULTS
p53 mutant gene overexpression was more frequently detected in HM (68%) than in normal placentas (22%)(p<0.05). bcl-2 was overexpressed in 31% of HM and 11% of normal placenta, but the difference was statistically insignificant (P > 0.05). The difference in bcl-2 and p53 expression between group A and group B was not observed (P>0.05). There was no inverse relationship between p53 and bcl-2 expression in group A, and group B (P>0.05).
CONCLUSIONS
p53 gene mutation may play a mle in the process of HM development, but p53 and bcl-2 were not associated with the genesis of GTI' from H-mole. More studies are needed to identify the molecular process in the progression of the GTD.

2,338 View
15 Download

The Expression of Phospholipase C-gamma1 and Its Cellular Characteristics: Dong Young Noh, Han Sung Kang, Young Chul Kim, In Ae Park, Yeo Kyu Yong, Seung Keun Oh, Kuk Jin Choe; J Korean Cancer Assoc. 1998;30(3):457-463.

Abstract PDF: BACKGROUND
The activation of phospholipase C(PLC) is one of the early cellular events in various growth process, including malignant transformation. PLC-gamma1 is activated through direct interaction with growth factor receptor tyrosine kinase. MATERIAL AND METHODS: Using immunoblot assay, we evaluated overexpression of PLC-gamma1 expression in twenty human breast cancer tissues. It was also determined whether there was any connection between other prognostic factors(numbers of metastatic axillary nodes, nuclear and histological grade, c-erbB2, p53 and E-cadherin) and the overexpression of PLC-gamma1 protein.
RESULTS
Seventeen of 20 breast cancer tissues showed overexpression of PLC-gamma1, which was corresponded to that seen on the immunohistochemistry( kappa= 0.8275, p = 0.003). Of 3 tumor markers, immunohistochemically determined, positive expression of E-cadherin only was associated with PLC-gamma1 protein overexpression in a range of statistical significance (p=0.045, kappa=0.607).
CONCLUSION
PLC-gamma1 overexpression might be pathogenic trigger involved in breast cancer and the relationship between expression of E-cadherin and PLC-gamma1 would require further elucidation.

2,501 View
14 Download

Clinicopathologic Analysis of 40 Mucinous Breast Carcinomas: Woo Jin Choe, Han Sung Kang, Ji Soo Kim, Dong Young Noh, In Ae Park, Yeo Kyu Yong, Seung Keun Oh, Kuk Jin Choe; J Korean Cancer Assoc. 1998;30(1):106-112.

Abstract PDF: PURPOSE
Mucinous carcinoma of breast was known to have a lower lymph node metastasis and better prognosis than other type of breast cancer. This study was performed to clarify the clinicopathologic features and prognosis of mucinous breast carcinoma.
MATERIALS AND METHODS
We reviewed clinicopathologic features of 40 patients diagnosed mucinous breast carcinoma from Jan. 1985 to Dec. 1995 and compared 31 patients of unmixed mucinous breast carcinoma with 1128 patients of infiltrating ductal carcinoma group.
RESULTS
Of total 40 mucinous ca., 31 cases were unmixed type showing no component of invasive ductal component(IDC) and 9 cases were mixed type showing IDC. The average age of the patients was 47 ranging from 31 to 71 years. The most common symptom was palpable breast mass(38 cases, 95%). According to TNM classification, the numbers of unmixed type were following, stage I 14 cases(45%), stage II 15 cases(48%), and stage III 2 cases(7%), and of mixed type, stage I 1 cases(11%), and stage II was 8 cases(89%). Axillary lymph node metastasis was shown to be negative in 26 cases of unmixed mucinous carcinoma(84%), whereas it did in 544 cases of infilterating ductal carcinoma(48%)(p<0.05). Because all patients with unmixed mucinous carcinoma survived except 2 patients who died of cancer unrelated causes, it was impossible to analyze the difference of outcome in unmixed mucinous carcinoma and infilterating ductal carcinoma(5YSR: 81%).
CONCLUSION
Considering unmixed mucinous carcinoma had fewer axillary lymph node metatasis than infiterating ductal carcinoma, it may be concluded that unmixed mucinous carcinoma had better prognosis.

2,624 View
12 Download

A Clinicopathologic Analysis of Medullary Breast Cancer: Myung Chul Chang, Jee Soo Kim, Ik Jin Yun, Dong Young Noh, Yeo Kyu Youn, Seung Keun Oh, Kuk Jin Choe, In Ae Park; J Korean Cancer Assoc. 1997;29(3):422-428.

Abstract PDF: PURPOSE
Medullary carcinoma of breast was known to have a better prognosis than other breast cancer, but the histopathological definition of medullary carcinoma has varied with time. This study was performed to clarify the clinicopathologic features of medullary breast cancer.
MATERIALS AND METHODS
Twenty cases of breast cancer originally were diagnosed as medullary carcinoma at the Department of Surgery, Seoul National University Hospital from Jan. 1985 to Jun. 1995. The whole cases were reviewed and reclassified using the strictly defined histologic criteria applied by Ridolfi et al.
RESULTS
When reclassified, 16 tumors fulfilled the criteria of typical medullary cancer. But the rest 4 tumors were found to be nonmedullary cancer. The patients ranged from 29 to 69 years in age with an average of 49. The main symptom was the painless mass. The diameter of the tumor ranged from 1 to 8 cm with a mean size of 2.7 cm. The axillary lymph node was positive in three cases. The estrogen receptor was positive in 10%, and the progesterone receptor was positive in 20% of the cases. There were no local recurrences or distant metastasis during a mean follow-up period of 5.5 years.. All patients survived until the last follow-up.
CONCLUSION
Medullary breast cancer has good prognosis but strict, uniform histopathological diagnostic criteria are needed.

2,831 View
14 Download

Immunohistochemical assay of cathepsin-D in breast carcinomas:comparison with age tumor size, lymphnode invasiveness and estrogen receptor: Se Hwan Han, Dong Young Roh, Kook Jin Choi, Jin Bok Kim, Wang Jae Lee, In Ae Park; J Korean Cancer Assoc. 1993;25(5):658-663.

Abstract PDF: No abstract available.

2,150 View
12 Download

DNA ploidy, S-phase activity and c-erbB-2 oncogene protein expression in breast cancer and its relationship to prognosis: Dong Young Noh, Kuk Jin Choe, Jin Pok Kim, In Ae Park, Seong Hoe Park, Keun Young Yoo; J Korean Cancer Assoc. 1992;24(1):73-81.

Abstract PDF: No abstract available.

2,241 View
13 Download

Study on the Growth Pattern and Histogenetic Classification of Peripheral Adenocarcinomas in the Lung: Jeong Wook Seo, In Ae Park, Eui Keun Ham; J Korean Cancer Assoc. 1990;22(3):374-386.

Abstract PDF: The relationships between gross, microscopic and ultrastructural features of pulmonary adenocarcinomas and the morphologic significance of lepidic growth are studied using nine cases of peripheral adenocarcinomas with lepidic growth. They include three bronhioloalveolar carcinomas ( BAC's), two acinar adenocarcinomas, two papillary adenocarcinoms and two metastatic adenocarcinomas. Ill-defined consolidating mass was seen in three cases of BAC's and one acinar adenocarinoma. Other cases of acinar, papillary types and metastatic tumors were classified into secretory type or poorly differentiated type and metastatic adenocarcinomas showed mixture of the types. Mucin secreting cell by light microscopy showed apical clustering of electron-lucent mucin vacuoles by electron microscopy, but non-secretory type showed variable features of electron microscopy, but non-secretory type showed variable features of Clara cell, type II pneumocytes of indeterminate cells. Tumor growing along the alveolar wall was encountered in every type of the cases byt the distribution and microscopic findings were different according to the light microscopic types. The lepidic pattern was seen homogeneously in the whole tumor field in BAC's but was seen only at the peripheral zone of the tumor in the other instances. We could classify the microscopic features of lepidic growth into three patterns based on the findings in BAC's. Regular lepidic growth confined to the alveolar wall was seen only in BAC. One paillary adenocarcinoma and one BAC showed multicentric nodules which was composed of micropapillary projections into the alveolar spaces in addition to the tumor cells covering the preexisting alveolar wall. Other cases showed intraluminal polypoid growth and shedding into the lumina and numerous tumor balls were scattered. The significance of these morphologic patterns of lepidic growth is undetermined, however we could speculate that first and second patterns are well differentiated forms but polypoid shedding pattern is poorly differentiated form with rapid aerogenous spread and has more frequent chance to be detected by sputum cytology.

2,148 View
15 Download

Discrepancies between the Biochemical and Immunohistochemical Assays of the Progestrone Receptor : Correlations with Classical Prognostic Factors in Breast Carcinoma: Dae Yeon Kim, Se Hwan Han, Dong Young Noh, In Ae Park, June Key Chung, Kuk Jin Choe; J Korean Cancer Assoc. 1995;27(1):69-77.

Abstract PDF: Breast cancer specimens from 77 patients were assayed for the presence of progesterone receptors (PR) utilizing the biochemical assay (Dextran Coated Charcoal) and immunohistochemical assay (ICA). The PR status of these patients were evaluated in respect to age and size of the tumor, axillary lymph-node metastasis, and cell differentiation according to the each method. The number of PR positive tumor was 23 cases (29.9%) in DCC and 42 cases (54.5%) in PR-ICA. The concordance of both assays is 0.304. There was no correlation between PR status and the age of patients in both assays. There was increase of PR expression in smaller tumor, but that was significanfin only ICA (P<0.05). The relationship between axillary lymph- node metastasis and PR expression was not proven by ICA but there was significant increase of PR positive ratio in lesser axillary lymph-node metastasis with DCC method (P<0.05). The relationship between TNM stage and PR expression was not proven by ICA method but there was significant increase of PR positive ratio in early TNM stage with DCC method (P<0.05). The relationship between histologic grade and PR expression was not observed. In this study, the results of ICA showed higher expression rate than DCC method. The ICA was correlated with the size of tumor, while the DCC assay was correlated with the axillary lymph-node metastasis and stage.

2,365 View
12 Download

First
Prev
Page of 1
Next
Last

Search